“Given the convergence of evidence that GLP-1 receptor agonists (e.g., semaglutide) and expanding SGLT2 inhibitor use deliver demonstrable weight-loss, cardiovascular, renal, and neurological benefits—and that emerging AI-driven peptide therapies show promise in stroke intervention—and noting no substantive conflicts among these pillars, we assign an overall Moderate Risk Posture with a favorable tilt. Persistent anxiety over ischemic stroke burden underscores the importance of continued vigilance but does not indicate any unresolved evidence divergence.”